A carregar...
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*
AIMS: To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea. METHODS: In this 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicentre study, participants...
Na minha lista:
Main Authors: | , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Blackwell Publishing Ltd
2012
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3466411/ https://ncbi.nlm.nih.gov/pubmed/22564709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1463-1326.2012.01618.x |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|